WYETH-AYERST CORDARONE I.V. FOR LIFE-THREATENING ARRHYTHMIAS
WYETH-AYERST CORDARONE I.V. FOR LIFE-THREATENING ARRHYTHMIAS shows an 86% survival rate after 48 hours in three pivotal studies, including in patients with frequently recurring ventricular fibrillation and hemodynamically destabilizing tachycardia unresponsive to other antiarrhythmic therapy in the previous 72 hours. Based on the strength of these clinical trial results in patients who do not respond to lidocaine, procainamide or bretylium, FDA's Cardiovascular & Renal Drugs Advisory Committee on Oct. 14 voted 5-2 in favor of approval for the I.V. version of Wyeth-Ayerst's amiodarone.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth